RAGE and its ligands in breast cancer progression and metastasis.

IF 3.1 Q2 ONCOLOGY Oncology Reviews Pub Date : 2025-01-03 eCollection Date: 2024-01-01 DOI:10.3389/or.2024.1507942
Madalina Coser, Bogdan Mihai Neamtu, Bogdan Pop, Calin Remus Cipaian, Maria Crisan
{"title":"RAGE and its ligands in breast cancer progression and metastasis.","authors":"Madalina Coser, Bogdan Mihai Neamtu, Bogdan Pop, Calin Remus Cipaian, Maria Crisan","doi":"10.3389/or.2024.1507942","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is the most common form of cancer diagnosed worldwide and the leading cause of death in women globally, according to Globocan 2020. Hence, investigating novel pathways implicated in cancer progression and metastasis could lead to the development of targeted therapies and new treatment strategies in breast cancer. Recent studies reported an interplay between the receptor for advanced glycation end products (RAGE) and its ligands, S100 protein group, advanced glycation end products (AGEs) and high-mobility group box 1 protein (HMGB1) and breast cancer growth and metastasis.</p><p><strong>Materials and methods: </strong>We used articles available in the NCBI website database PubMed to write this scoping review. The search words used were 'RAGE receptor' AND/OR 'breast cancer, RAGE ligands, glycation end products'. A total of 90 articles were included. We conducted a meta-analysis to assess the relationship between the RAGE rs1800624 polymorphism and breast cancer risk using fixed-effect or random-effect models to calculate odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs).</p><p><strong>Results: </strong>RAGE upon activation by its ligands enhances downstream signaling pathways, contributing to breast cancer cells migration, growth, angiogenesis, metastasis, and drug resistance. In addition, studies have shown that RAGE and its ligands influence the way breast cancer cells interact with immune cells present in the tumor microenvironment (macrophages, fibroblasts), thus regulating it to promote tumor growth and metastasis.</p><p><strong>Conclusion: </strong>Breast cancers with a high expression of RAGE are associated with poor prognosis. Targeting RAGE and its ligands impairs cell invasion and metastasis, showing promising potential for further research as potential prognostic biomarkers or targeted onco-therapeutics.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"18 ","pages":"1507942"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739297/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/or.2024.1507942","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Breast cancer is the most common form of cancer diagnosed worldwide and the leading cause of death in women globally, according to Globocan 2020. Hence, investigating novel pathways implicated in cancer progression and metastasis could lead to the development of targeted therapies and new treatment strategies in breast cancer. Recent studies reported an interplay between the receptor for advanced glycation end products (RAGE) and its ligands, S100 protein group, advanced glycation end products (AGEs) and high-mobility group box 1 protein (HMGB1) and breast cancer growth and metastasis.

Materials and methods: We used articles available in the NCBI website database PubMed to write this scoping review. The search words used were 'RAGE receptor' AND/OR 'breast cancer, RAGE ligands, glycation end products'. A total of 90 articles were included. We conducted a meta-analysis to assess the relationship between the RAGE rs1800624 polymorphism and breast cancer risk using fixed-effect or random-effect models to calculate odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs).

Results: RAGE upon activation by its ligands enhances downstream signaling pathways, contributing to breast cancer cells migration, growth, angiogenesis, metastasis, and drug resistance. In addition, studies have shown that RAGE and its ligands influence the way breast cancer cells interact with immune cells present in the tumor microenvironment (macrophages, fibroblasts), thus regulating it to promote tumor growth and metastasis.

Conclusion: Breast cancers with a high expression of RAGE are associated with poor prognosis. Targeting RAGE and its ligands impairs cell invasion and metastasis, showing promising potential for further research as potential prognostic biomarkers or targeted onco-therapeutics.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
RAGE及其配体在乳腺癌进展和转移中的作用。
导读:根据Globocan 2020的数据,乳腺癌是全球诊断出的最常见的癌症形式,也是全球女性死亡的主要原因。因此,研究与癌症进展和转移有关的新途径可能会导致乳腺癌靶向治疗和新治疗策略的发展。最近的研究报道了晚期糖基化终产物受体(RAGE)及其配体、S100蛋白组、晚期糖基化终产物(AGEs)和高迁移率组1蛋白(HMGB1)与乳腺癌生长和转移之间的相互作用。材料和方法:我们使用NCBI网站数据库PubMed中的文章来撰写这篇范围综述。搜索词是“RAGE受体”和/或“乳腺癌,RAGE配体,糖基化终产物”。共纳入90篇文章。我们采用固定效应或随机效应模型计算优势比(ORs)及其相应的95%置信区间(95% ci),对RAGE rs1800624多态性与乳腺癌风险之间的关系进行了meta分析。结果:RAGE被其配体激活后,可增强下游信号通路,参与乳腺癌细胞的迁移、生长、血管生成、转移和耐药。此外,研究表明RAGE及其配体影响乳腺癌细胞与肿瘤微环境中存在的免疫细胞(巨噬细胞、成纤维细胞)相互作用的方式,从而调节其促进肿瘤生长和转移。结论:RAGE高表达的乳腺癌预后较差。靶向RAGE及其配体可损害细胞的侵袭和转移,显示出作为潜在预后生物标志物或靶向肿瘤联合治疗药物的进一步研究前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncology Reviews
Oncology Reviews ONCOLOGY-
CiteScore
6.30
自引率
0.00%
发文量
9
审稿时长
9 weeks
期刊介绍: Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.
期刊最新文献
Status analysis of quality control of administered infusion solution with cytotoxic drugs. Biomarker testing in lung cancer: from bench to bedside. RAGE and its ligands in breast cancer progression and metastasis. A case of synovial sarcoma of the right mid-thigh and literature review. Lymphadenectomy in the treatment of sarcomas - indications and technique.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1